Abstract:BACKGROUND:Pancreatic stellate cells (PSCs, which produce the stroma of pancreatic cancer (PC)) interact with cancer cells to facilitate PC growth. A candidate growth factor pathway that may mediate this interaction is the HGF-c-MET pathway.METHODS:Effects of HGF inhibition (using a neutralising antibody AMG102) alone or in combination with gemcitabine were assessed (i) in vivo using an orthotopic model of PC, and (ii) in vitro using cultured PC cells (AsPC-1) and human PSCs.RESULTS:We have shown that human PSCs (hPSCs) secrete HGF but do not express the receptor c-MET, which is present predominantly on cancer cells. HGF inhibition was as effective as standard chemotherapy in inhibiting local tumour growth but was significantly more effective than gemcitabine in reducing tumour angiogenesis and metastasis. HGF inhibition has resulted in reduced metastasis; however, interestingly this antimetastatic effect was lost when combined with gemcitabine. This suggests that gemcitabine treatment selects out a subpopulation of cancer cells with increased epithelial-mesenchymal transition (EMT) and stem-cell characteristics, as supported by our findings of increased expression of EMT and stem-cell markers in tumour sections from our animal model. In vitro studies showed that hPSC secretions induced proliferation and migration, but inhibited apoptosis, of cancer cells. These effects were countered by pretreatment of hPSC secretions with a HGF-neutralising antibody but not by gemcitabine, indicating a key role for HGF in PSC-PC interactions.CONCLUSIONS:Our studies suggest that targeted therapy to inhibit stromal-tumour interactions mediated by the HGF-c-MET pathway may represent a novel therapeutic approach in PC that will require careful modelling for optimal integration with existing treatment modalities.

Homoharringtonine Sensitizes Pancreatic Cancer to Erlotinib by Direct Targeting and Mirna-130B-3p-mediated EphB4-JAK2-STAT3 Axis.

Homoharringtonine Inhibits the Akt Pathway and Induces in Vitro and in Vivo Cytotoxicity in Human Multiple Myeloma Cells

Homoharringtonine Affects the Jak2-Stat5 Signal Pathway Through Alteration of Protein Tyrosine Kinase Phosphorylation in Acute Myeloid Leukemia Cells

[Effect of Homoharringtonine Combined with AG490 on JAK2-STAT5 Associated Signal Pathway in HEL Cells].

Homoharringtonine is Synergistically Lethal with BCL-2 Inhibitor APG-2575 in Acute Myeloid Leukemia

Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells.

Apatinib Enhances Chemosensitivity of FLT3-ITD Mutations acute Myeloid Leukemia Cells to Homoharringtonine Via VEGFR2 Pathway

Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells

Homoharringtonine Could Induce Quick Protein Synthesis of PSMD11 Through Activating MEK1/ERK1/2 Signaling Pathway in Pancreatic Cancer Cells

Homoharringtonine promotes non-small-cell lung cancer cell death via modulating HIF-1α/ERβ/E2F1 feedforward loop

HGF/c-Met pathway inhibition combined with chemotherapy increases cytotoxic T-cell infiltration and inhibits pancreatic tumour growth and metastasis

The Role of the Hepatocyte Growth Factor/c-Met Pathway in Pancreatic Stellate Cell-Endothelial Cell Interactions: Anti-angiogenic Implications in Pancreatic Cancer

Targeting of phospho-eIF4E by homoharringtonine eradicates a distinct subset of human acute myeloid leukemia

The Underlying Molecular Mechanism of Intratumoral Radiofrequency Hyperthermia-Enhanced Chemotherapy of Pancreatic Cancer

The small-molecule drug homoharringtonine targets HSF1 to suppress pancreatic cancer progression

Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines

Uncovering the Action Mechanism of Homoharringtonine Against Colorectal Cancer by Using Network Pharmacology and Experimental Evaluation

Homoharringtonine Suppresses LoVo Cell Growth by Inhibiting EphB4 and the PI3K/AKT and MAPK/EKR1/2 Signaling Pathways

Homoharringtonine inhibits the progression of hepatocellular carcinoma by suppressing the PI3K/AKT/GSK3β/Slug signaling pathway

ESE3/EHF, a Promising Target of Rosiglitazone, Suppresses Pancreatic Cancer Stemness by Downregulating CXCR4.

Hepatocyte Growth Factor Inhibition: a Novel Therapeutic Approach in Pancreatic Cancer.